Document:

<PAGE>
                                                                    EXHIBIT 10.8

                                                CONFIDENTIAL TREATMENT REQUESTED

                                SERVICE AGREEMENT

      This agreement ("Agreement") made as of March 31, 1999 by and between
SNYDER HEALTHCARE SALES INC., a New Jersey corporation ("SHS") and ADEZA
BIOMEDICAL CORPORATION, a Delaware corporation ("CLIENT")

                              W I T N E S S E T H:

      WHEREAS, SHS provides integrated outsourced sales and marketing solutions
worldwide, including client field forces, to the healthcare industry; and

      WHEREAS, CLIENT is in the healthcare industry and has need of certain
services of SHS contained in the Scope of Services set forth in Schedule A to
this Agreement, as the same may be amended from time to time; and

      WHEREAS, SHS and CLIENT desire to enter into an agreement under which SHS
will provide such services to CLIENT.

      NOW, THEREFORE, in consideration of the premises and other good and
valuable consideration, the receipt and adequacy of which is hereby
acknowledged, it is agreed as follows:

1.    TERM

      The Agreement shall be in effect as of March 31, 1999 and shall remain in
effect through and including May 14, 2001 (the "Term"). This Agreement will
automatically renew for additional periods of one year each (each an "Additional
Term"), unless CLIENT gives written notice of non-renewal to the other at least
sixty (60) days prior to the end of the Term or any Additional Term. The amount
of compensation (both fixed and variable fees) payable to SHS

                                      -1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

under Section 3.1 of this Agreement during any Additional Term will be as
mutually agreed upon.

2.    SCOPE OF SERVICES AND PROFESSIONALISM AND COMPLIANCE

      2.1   The Scope of Services.

      The Scope of Services to be provided under this Agreement is set forth in
Schedule A to the Agreement as the same may be amended from time to time, each
iteration of which shall be dated and signed by an authorized person of each
party to this Agreement. Included with Schedule A is a Summary of Services,
Expenses, Expense Responsibility and Reimbursements ("Summary of Services")
setting forth services, expenses, responsibility for expenses and reimbursement
obligations; the Summary of Services is a part of this Agreement and not simply
a description of what this Agreement contains. The Summary of Services may be
amended from time to time with each alteration dated and signed by an authorized
person of each party. Should CLIENT elect to change the Scope of Services to be
provided under this Agreement, the compensation paid to SHS will be
appropriately adjusted to reflect the change, upon written agreement of the
parties.

      2.2   Professionalism and Compliance.

      SHS shall perform the Services, and shall require each Representative to
perform the Services (i) in a professional manner consistent with industry
standards; (ii) in conformance with that level of care and skill ordinarily
exercised by other professional contract sales organizations in similar
circumstances; and (iii) in compliance with all applicable local, state and
federal laws and regulations.

                                      -2-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

3.    COMPENSATION AND REIMBURSEMENT

      3.1   Compensation.

      CLIENT shall pay SHS compensation for the Scope of Services performed
under this Agreement. The amount of compensation to be paid to SHS shall consist
of one or more fixed fees for services and may also consist of one or more
variable fees for services, all of the fixed and variable fees being set forth
on Schedule B to this Agreement (as the same may be amended from time to time
with each iteration dated and signed by an authorized person of each party to
this Agreement).

      3.2   Reimbursement.

      CLIENT shall also reimburse SHS, and/or persons provided by SHS to perform
the Scope of Services, for certain expenses incurred in performing the services
to be provided under this Agreement, as more fully set on the Summary of
Services.

      3.3   Payment Due

      Invoices are due and payable [***] following receipt by CLIENT. Invoices
shall be sent to Accounts Payable, Adeza Biomedical Corporation, 1240 Elko Dr.,
Sunnyvale, CA 94089. The invoices will clearly state fixed and variable costs
and their categories. Adeza shall not be liable for any fixed costs incurred
more than ninety (90) days prior to the date on the invoice. Invoices will be
remitted by CLIENT to Accounts Receivable, Snyder Healthcare Sales, Inc., 200
Cottontail Lane, Somerset, NJ 08873.

      In addition to SHS's right to terminate this Agreement under Section 10.2
in the case of non-payment, if SHS elects not to terminate the Agreement, CLIENT
shall pay a finance charge

                                      -3-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

of [***] for each invoice past due for more than [***] from the receipt of
invoice by the CLIENT.

      3.4   Inspection Right

      Upon prior written notice and at mutually agreeable times, CLIENT has the
right to inspect the books and records of SHS which relate to this Agreement for
the purpose of auditing the documents and invoices with respect to the Scope of
Services provided hereunder.

4.    REPRESENTATIONS OF THE PARTIES

      4.1   SHS Representations.

      SHS represents that:

            a.    it has the requisite expertise, experience and skill to render
                  the Services and that it shall use all reasonable efforts to
                  cause the Services to be performed in a competent, efficient
                  and professional manner.

            b.    the execution, delivery and performance of this Agreement by
                  SHS and the consummation of the transaction contemplated has
                  been duly authorized by all requisite corporate action; that
                  the Agreement constitutes the legal, valid, and binding
                  obligation of SHS, enforceable in accordance with its terms
                  (except to the extent enforcement is limited by bankruptcy,
                  insolvency, reorganization or other laws affecting creditors'
                  rights generally and by general principles of equity); and
                  that this Agreement and performance hereunder does not violate
                  or constitute a breach under any organizational document of
                  SHS or any contract, other form of

                                      -4-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                  agreement, or judgment or order to which SHS is a party or by
                  which it is bound.

            c.    SHS will maintain insurance with financially sound carriers in
                  the amounts and types (with the deductibles or retentions) as
                  set forth in Schedule C to this Agreement, as the same may be
                  amended from time to time; each iteration of which shall be
                  dated and signed by an authorized person of each party to the
                  Agreement.

      4.2   Client Representations.

      CLIENT represents that:

            a.    The execution, delivery and performance of this Agreement by
      CLIENT and the consummation of the transaction contemplated has been duly
      authorized by all requisite corporate action; that the Agreement
      constitutes the legal, valid, and binding obligation of CLIENT,
      enforceable in accordance with its terms (except to the extent enforcement
      is limited by bankruptcy, insolvency, reorganization or other laws
      affecting creditors' rights generally and by general principles of
      equity); and that this Agreement and performance hereunder does not
      violate or constitute a breach under any organizational document of CLIENT
      or any contract, other form of agreement, or judgment or order to which
      CLIENT is a party or by which it is bound.

            b.    CLIENT will maintain insurance with financially sound carriers
      or through one or more financially sound self-insurance arrangements in
      the amounts and types (and with the deductibles or retentions) as set
      forth in Schedule C to this

                                      -5-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      Agreement, as the same may be amended from time to time; each iteration of
      which shall be dated and signed by an authorized person of each party to
      the Agreement.

5.    CONFIDENTIALITY

      During the performance of the Services contemplated by this Agreement,
each party may learn confidential, proprietary, and/or trade secret information
of the other party ("Confidential Information"). The party disclosing
Confidential Information shall be referred to as the "Disclosing Party" and the
party receiving Confidential Information shall be referred to as the "Receiving
Party."

      Confidential Information means any information, unknown to the general
public, which is disclosed by the Disclosing Party to the Receiving Party under
this Agreement. Confidential Information includes, without limitation,
technical, trade secret, commercial and financial information about either
party's (a) research or development; (b) marketing plans or techniques, contacts
or customers; (c) organization or operations; (d) business development plans
(i.e., licensing, supply, acquisitions, divestitures or combined marketing); and
(e) products, licenses, trademarks, patents, other types of intellectual
property or any other contractual rights or interests. The Receiving Party shall
neither use nor disclose Confidential Information from the Disclosing Party for
any purpose other than is specifically allowed by this Agreement.

      Upon the expiration or termination of this Agreement, the Receiving Party
shall return to the Disclosing Party all tangible forms of Confidential
Information, including any and all copies and/or derivatives of Confidential
Information made by either party or their employees as well as any writings,
drawings, specifications, manuals or other printed or electronically stored
material based on or derived from, Confidential Information. Any material or
media not subject to return

                                      -6-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

must be destroyed. The Receiving Party shall not disclose to third parties any
Confidential Information or any reports, recommendations, conclusions or other
results of work under this Agreement without prior consent of an officer of the
Disclosing Party. The obligations set forth in this Article 5, including the
obligations of confidentiality and non-use shall be continuing and shall survive
the expiration or termination of this Agreement and will continue for a period
of five (5) years.

      The obligations of confidentiality and non-use set forth herein shall not
apply to the following: (i) Confidential Information at or after such time that
it is or becomes publicly available through no fault of the Receiving Party;
(ii) Confidential Information that is already independently known to the
Receiving Party as shown by prior written records; (iii) Confidential
Information at or after such time that it is disclosed to the Receiving Party by
a third party with the legal right to do so; (iv) Confidential Information
required to be disclosed pursuant to judicial process, court order or
administrative request, provided that the Receiving Party shall so notify the
Disclosing Party sufficiently prior to disclosing such Information as to permit
the Disclosing Party to seek a protective order.

6.    INDEPENDENT CONTRACTOR

      SHS and its directors, officers, and the persons providing services under
the Agreement are at all times independent contractors with respect to CLIENT.
Persons provided by SHS to perform Services shall not be deemed employees of
CLIENT. CLIENT shall not be responsible for SHS's acts or the acts of its
officers, agents and employees while performing the Services whether on CLIENT
premises or elsewhere.

                                      -7-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      SHS shall not be responsible for any cost, however, attributable to: (i)
any actions by CLIENT that caused a person provided by SHS to perform services
under this Agreement to be reclassified as an employee of CLIENT, (ii) any
unlawful or discriminatory acts of CLIENT, and (iii) language in any CLIENT
benefit plan that is deemed to extend coverage to person provided by SHS to
perform services under the Agreement based on their activities under this
Agreement.

7.    OWNERSHIP OF PROPERTY AND DEVELOPMENTS

      Unless otherwise provided in a Schedule attached to this Agreement
(including without limitation Schedule A-1A), all materials and documents
supplied to either party during the Term of this Agreement, by or through the
other, which relate to the Services shall be the sole and exclusive property of
the originator of those materials and developments. Notwithstanding the
foregoing, all materials and documents or portions thereof, relating to the
fetal fibronectin technology shall be the sole and exclusive property of CLIENT.
Each party agrees to hold all such property and developments, confidential in
accordance with Section 5 of this Agreement. All property and developments,
distributed to licensed practitioners, shall be returned, delivered or assigned
to the originating party upon the expiration or termination of this Agreement.
The provisions of paragraph (b) of Schedule A-1A will survive any expiration or
termination of this Agreement.

8.    FINDER'S FEE AND THIRD PARTY EMPLOYMENT

      8.1   Employment or Retention by CLIENT.

      CLIENT may not employ or retain any person employed by or used by SHS to
provide services under this Agreement on or prior to October 1, 1999 and may not
employ or retain such person thereafter, during the Term of this Agreement,
unless SHS is given [***] advance notice of such employment and the applicable
finder's fee is paid to SHS by CLIENT in the amount set

                                      -8-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

forth in Schedule B to this Agreement (as the same may be amended from time to
time, each iteration of which shall be dated and signed by an authorized person
of each party to this Agreement).

      8.2   Employment or Retention by Third Party.

      Should any third party (which provides integrated outsourced sales and
marketing solutions) with a contract with, or seeking to enter into an
arrangement with, CLIENT (under which the third party is supplying or will
supply services to CLIENT, which services are comparable to the Scope of
Services), employ or retain (as a consultant or otherwise) during the Term of
this Agreement or within [***] after the termination of this Agreement, any
person employed by or used by SHS to provide services under this Agreement, such
third party shall pay SHS [***] for each person so employed or retained as
liquidated damages. To the extent the amount payable to SHS under the immediate
prior sentence is not paid within two weeks of invoicing, CLIENT shall pay SHS
that amount.

9.    INDEMNIFICATION

      9.1   SHS Indemnifies.

      SHS agrees to indemnify and hold CLIENT, its officers, directors, agents
and employees harmless from and against any and all liabilities, losses,
proceedings, actions, damages, claims or expenses of any kind, including costs
and attorneys' fees which result from (i) any negligent or willful acts or
omissions, (ii) acts or omissions outside the scope of this Agreement or (iii)
any breach of this Agreement by SHS, its agents, directors, officers or
employees, in connection with the representations, duties and obligations of SHS
under this Agreement.

      9.2   CLIENT Indemnifies.

                                      -9-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      CLIENT agrees to indemnify and hold SHS, its officers, directors, agents,
and employees harmless from and against any and all liabilities, losses,
proceedings, actions, damages, claims or expenses of any kind, including costs
and attorneys' fees which result from (i) any negligent or willful acts or
omissions by CLIENT, its agents, directors, officers or employees, in connection
with the representations, duties and obligations of CLIENT under this Agreement
or (ii) products liability claims relating to any product of CLIENT involved
with the services provided by SHS under this Agreement, except to the extent
that such product liability claim would not have arisen but for any action or
omission for which SHS is obligated to indemnify CLIENT pursuant to Section 9.
1.

      9.3   Indemnification Process.

      Any indemnity available hereunder shall be dependent upon the party
seeking indemnity providing prompt notice to the indemnitor of any claim or
lawsuit giving rise to the indemnity provided, however that failure to comply
with this notice requirement shall not reduce the indemnitor's indemnification
obligation except to the extent that the indemnitor is prejudiced as a result.
Thereafter, the indemnitor shall have exclusive control over the handling of the
claim or lawsuit, and the indemnitee shall provide reasonable assistance to the
indemnitor in defending the claim, at indemnitor's expense.

10.   TERMINATION

      10.1  60 Day Notice

      Notwithstanding any implication raised by the renewal provisions of
      Section 2 of this Agreement, CLIENT may terminate this Agreement at any
      time by giving sixty (60) days prior written notice to SHS.

                                      -10-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      10.2  Immediate Termination

            This Agreement may be terminated effective immediately upon giving
            written notice as follows:

            a.    by SHS, if payment to SHS by CLIENT is not made when due and
                  such payment is not made within thirty (30) days from the date
                  of notice to CLIENT of such nonpayment; or

            b.    by either party, in the event that the other party has
                  committed a material breach of this Agreement and such breach
                  has not been cured within thirty (30) days of receipt of
                  written notice from the non-breaching party of such breach; or

            c.    by either party, in the event that the other party has become
                  insolvent or has been dissolved or liquidated, filed or has
                  filed against it, a petition in bankruptcy and such petition
                  is not dismissed within sixty (60) days of the filing, makes a
                  general assignment for the benefit of creditors; or has a
                  receiver appointed for a substantial portion of its assets.

      10.3  Survival

      Upon the effective date of termination or expiration, the parties shall
have no further obligation to each other (other than those set forth in Sections
5, 7, 8 and 9), except that CLIENT shall: (a) pay the amount set forth or
provided for on Schedule B to this Agreement in the case of termination; (b) pay
the amount of any fixed and/or variable fees due under Section 3.1 of this
Agreement for Services actually performed by SHS through the date termination or
expiration is effective; and (c) pay any reimbursement amount due under Section
3.2 of this Agreement for

                                      -11-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

expenses related to the performance of Services through the date termination or
expiration is effective.

11.   MISCELLANEOUS

      11.1  Assignment.

      Neither SHS nor CLIENT may assign this Agreement or any of its rights,
duties or obligations hereunder without the other party's prior written consent,
provided, however, that either SHS or CLIENT may assign its rights, duties and
obligations as part of an acquisition of SHS or CLIENT (whether by merger, sale
of all or substantially all of the assigning parties assets related to the
subject matter of this Agreement, or otherwise), as the case may be, so long as
the acquirer (i) is a financially capable business entity and (ii) expressly
assumes in writing those rights, duties and obligations under this Agreement and
this Agreement itself.

      11.2  Merger.

      This Agreement supersedes all prior arrangements and understandings
between parties related to the subject matter of this Agreement

      11.3  Force Majeure.

      Noncompliance with the obligations of this Agreement due to a state of
force majeure, the laws or regulations of any government, regulatory or judicial
authority, war, civil commotion, destruction of facilities and materials, fire,
earthquake or storm, labor disturbances, shortage of materials, failure of
public utilities or common carriers, and any other causes beyond the reasonable
control of the applicable party, shall not constitute a breach of contract.

      11.4  Severability.

                                      -12-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      If any provision of this Agreement is finally declared or found to be
illegal or unenforceable by a court of competent jurisdiction, both parties
shall be relieved of all obligations arising under such provision, but, if
capable of performance, the remainder of this Agreement shall not be affected by
such declaration or finding. The parties shall endeavor in good faith to agree
to an enforceable provision to replace the illegal or unenforceable provision in
order to effect the intent of the parties in entering into this Agreement.

      11.5  Amendment.

      This Agreement, including any attachments or exhibits entered into
hereunder, contains all of the terms and conditions of the agreement between the
parties and constitutes the complete understanding of the parties with respect
thereto. No modification, extension or release from any provision hereof shall
be affected by mutual agreement, acknowledgment, acceptance of contract
documents, or otherwise, unless the same shall be in writing signed by the other
party and specifically described as an amendment or extension of this Agreement.

      11.6  Governing Law.

      This Agreement shall be construed according to the laws of the State of
California.

      11.7  Counterparts.

      This Agreement may be executed in any number of counterparts, each of
which, when executed, shall be deemed to be an original and all of which
together shall constitute one and the same document.

      11.8  Notices.

      Any notices required or permitted under this Agreement shall be given in
person or sent by first class, certified mail to:

                                      -13-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

            SHS:

            Snyder Healthcare Sales, Inc.
            200 Cottontail Lane
            Somerset, NJ 08873
            Attention: William C. Pollock, President

      with a copy to:

            Peter D. Hutcheon, Esq.
            Norris, McLaughlin & Marcus, P.A.
            721 Route 202-206
            P.O. Box 1018
            Somerville, NJ 08876-1018

            CLIENT:

            Adeza Biomedical Corporation
            1240 Elko Drive
            Sunnyvale, CA 94089
            Attention: Emory Anderson, President

or to such other address or to such other person as may be designated by written
notice given from time to time during the term of this Agreement by one party to
the other.

                                      -14-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      WHEREFORE, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives.

                                              SNYDER HEALTHCARE SALES, INC.

                                              By: William C. Pollock
                                                  ------------------------
                                                  Name: William C. Pollock
                                                  Title: President
                                                  Date: 8/31/99

                                              ADEZA BIOMEDICAL CORPORATION

                                              By: Emory Anderson
                                                  ------------------------
                                                  Name: Emory Anderson
                                                  Title: President
                                                  Date: 9/2/99

                                      -15-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   SCHEDULE A
                                SCOPE OF SERVICES

      SHS will provide the following services (services to be provided must be
initialed).

<TABLE>
<CAPTION>
              INITIAL                       SCHEDULE
              IF SCHEDULE    SCHEDULE       SUBJECT
    DATE      APPLIES        NUMBER         MATTER
    ----      -------        ------         ------
<S>           <C>            <C>            <C>
                             A-1            Detailing to Targets

                             A-2            Sampling of Products to Targets

                             A-3            Manual Design

  N/A           N/A          A-4            Training of CLIENT personnel

  N/A           N/A          A-5            Event Staffing

  N/A           N/A          A-6            Additional/Special Services:
</TABLE>

                                            ------------------------------------

                                            ------------------------------------

                                            ------------------------------------

                                            ------------------------------------

      See the Summary of Services, Expenses, Expense Responsibility and
Reimbursement attached for information concerning the services and associated
costs.

                                     -1-A-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                     SUMMARY OF SERVICES, EXPENSES, EXPENSE
                        RESPONSIBILITY AND REIMBURSEMENTS

      SHS and CLIENT agree to the following Services, Expenses, Expense
Responsibility and Reimbursement obligations set out under headings in
alphabetical order. CLIENT shall promptly reimburse SHS (including reimbursement
for the reasonable expenses of individuals employed by SHS or provided by SHS to
perform the Scope of Services under the Agreement to which this Schedule is
attached) for the reasonable cost of the following items listed below under the
heading "SHS Passthrough Expense to CLIENT" within thirty (30) days of receipt
of timely submission of adequate documentation or as may be agreed to by the
parties:

<TABLE>
<CAPTION>
                                             SHS PASSTHROUGH
      CATEGORY           CLIENT EXPENSE     EXPENSE TO CLIENT   INCLUDED IN SHS FEE
      --------           --------------     -----------------   -------------------
<S>                   <C>                  <C>                  <C>
ADMINISTRATIVE        [***]                [***]                [***]
Business Cards
Copies
Office Supplies
Phone
Postage
Printing
Stationary
Overnight Courier
Other
ANALYTICS/HPR         [***]                [***]                [***]
Alignment
Call Plan
ROI Analysis
Other
AUTO COSTS            [***]                [***]                [***]
Mileage
Parking
Tolls
Other
BENEFITS              [***]                [***]                [***]
Medical
Dental
401(k)
Other
BILLABLE HRS          [***]                [***]                [***]
PROJECTED
BONUS INCENTIVES      [***]                [***]                [***]
SHS
Managers
Representatives
Client Server
Other
CALL REPORTING        [***]                [***]                [***]
</TABLE>

                                     -2-A-2-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

<TABLE>
<CAPTION>
                                             SHS PASSTHROUGH
      CATEGORY           CLIENT EXPENSE     EXPENSE TO CLIENT   INCLUDED IN SHS FEE
      --------           --------------     -----------------   -------------------
<S>                   <C>                  <C>                  <C>
CLIENT OVERHEAD       [***]                [***]                [***]
CONFERENCE CALLS      [***]                [***]                [***]
EQUIPMENT             [***]                [***]                [***]
Computer
Detail Bags
Faxes
Printer
Other
INSURANCE             [***]                [***]                [***]
Auto
Employment
Liability
Life
Travel
Workers Comp
Other
MAILOUT               [***]                [***]                [***]
Correspondence
Materials
Samples
Other
MANAGERS              [***]                [***]                [***]
Number
Full/Flex time
Dedicated/
Syndicated
MARKETING             [***]                [***]                [***]
MEETINGS              [***]                [***]                [***]
Client
Launch
Manager
Medical
Nat'l
POA
Training
Others
NATIONAL BUSINESS     [***]                [***]                [***]
DIRECTORS
Full/Part time
OTHER SERVICES        [***]                [***]                [***]
</TABLE>

                                     -3-A-3-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

<TABLE>
<CAPTION>
                                             SHS PASSTHROUGH
      CATEGORY           CLIENT EXPENSE     EXPENSE TO CLIENT   INCLUDED IN SHS FEE
      --------           --------------     -----------------   -------------------
<S>                   <C>                  <C>                  <C>
PROMOTIONAL           [***]                [***]                [***]
Entertainment
Gifts
Meals
Programs
Other
RECRUITING            [***]                [***]                [***]
Ads
Interviews
Referrals
Reference checks,
screens
Ride alongs
Other
REPORTING SYSTEM      [***]                [***]                [***]
Paper Based
SALARIES/WAGES        [***]                [***]                [***]
Managers
Reps
Client Services
Other
SALES MATERIALS       [***]                [***]                [***]
SALES REPRESENTATIVES [***]                [***]                [***]
Number
Full/Flex time
Dedicated/
 Syndicated
SAMPLES               [***]                [***]                [***]
SEVERANCE             [***]                [***]                [***]
SHS OVERHEAD          [***]                [***]                [***]
SPECIAL CLIENT        [***]                [***]                [***]
REQUESTS
STAFFING SERVICES     [***]                [***]                [***]
Number of Persons
Type of Event
Location
Dates
TARGETS               [***]                [***]                [***]
Physicians
Hospitals
Managed Care Entity
Other customers of
Adeza Products
</TABLE>

                                     -4-A-4-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

<TABLE>
<CAPTION>
                                             SHS PASSTHROUGH
      CATEGORY           CLIENT EXPENSE     EXPENSE TO CLIENT   INCLUDED IN SHS FEE
      --------           --------------     -----------------   -------------------
<S>                   <C>                  <C>                  <C>
TAXES                 [***]                [***]                [***]
Payroll
(FICA)
Other
TRAINING              [***]                [***]                [***]
Manager
rep
Home Study
Initial Training
Advanced Training
Computer
Selling Skills
Training Materials
Other
TRAVEL EXPENSES       [***]                [***]                [***]
Air
Auto
Hotel
Meals
Shuttle/Taxi
Tips
Incidentals
Other
VOICE MAIL            [***]                [***]                [***]
ALL OTHER FIELD       [***]                [***]                [***]
EXPENSE
</TABLE>

<TABLE>
<CAPTION>
                         TERM OF AGREEMENT
-------------------------------------------------------------------
TERM                                                      DATE
----                                                      ----
<S>                                                  <C>
Start Date
Implementation Date                                  March 31, 1999
End/Renew Date                                        May 14, 1999
                                                      May 14, 2001
</TABLE>

                                     -5-A-5-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

Date: 8/31/99                                           Date: 9/2/99

   William C. Pollock                                       Emory Anderson
------------------------                                ------------------------
 Authorized SHS Person                                   Authorized SHS Person

                                     -6-A-6-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                  SCHEDULE A-1
                    SCOPE OF SERVICES - DETAILING TO TARGETS

      Under the Agreement to which this Schedule A-1 is attached SHS will
provide individuals to serve as Sales Representatives to make Calls pursuant to
the Call Plan on Targets.

DEFINITIONS

      1.    "Call" means [***].

      2.    "Call Plan" means [***].

      3.    "Manager" means [***].

      4.    "National Business Director" means [***].

      5.    "Product" shall mean [***].

      6.    "Product Literature" shall mean [***].

      7.    "Reports" means [***].

      8.    "Sales Representative" means [***].

      9.    "Targets" means [***].

HIRE STATUS AND WORK SCHEDULE

      [***]

      [***]

CALLS AND TARGETS

      [***]

      [***]

            -  [***]

CALL ACTIVITY

      [***]

CLIENT SERVICES MANAGER

      [***]

                                     -1-A1-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

ALIGNMENT

      [***]

HIRING PROFILE

      [***]

TRAINING

      [***]

MEETINGS

      [***]

      [***]

PERFORMANCE

      [***]

CALL REPORTING

      [***]

REPRESENTATIONS AND UNDERTAKINGS

      In connection with this Schedule A-1:

      a.    SHS represents:

            i.    [***]

      b.    SHS will:

            i.    [***]

            ii.   [***]

            iii.  [***]

            iv.   [***]

      c.    CLIENT will:

            i.    [***]

            ii.   [***]

                                     -2-A1-2-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

            iii.  [***]

SALES FORCE STATUS

      [***]

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/ illegible                   /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                     -3-A1-3-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                  SCHEDULE A-1A
                              PRODUCTS and SERVICES

"Products and Services" for purposes of Schedule A-1 (to which this Schedule
A-1A is attached) and the Agreement to which Schedule A-1 (including this
Schedule A-1A) is attached means:

Products                             Description
--------                             -----------

Fetal fibronectin tests              Diagnostic Tests

Etegrity Services                    Diagnostic Service

Other CLIENT Products or Services

      (a) The Products and Services shall be promoted by SHS under trademarks
owned by or licensed to CLIENT. This Agreement does not constitute a grant to
SHS of any property right or interest in the Products and Services or the
trademarks owned by or licensed to CLIENT or an Affiliate of CLIENT and/or any
other intellectual property rights which CLIENT owns now or in the future. SHS
recognizes the validity of and the title of CLIENT to all their trademarks and
trade names in any country in connection with the Products and Services, whether
registered or not.

      (b) All information, data, writings, inventions and other work products,
in any form whatsoever, both tangible and intangible, developed as a result of
or in connection with SHS's performance of the Services, including without
limitation the Product Literature and all information gathered or developed by
the Representatives in the course of the Services (collectively, the "Works"),
shall be considered works made for hire pursuant to the Copyright Act of 1976
(if applicable), and/or shall be the sole and exclusive property of CLIENT.
CLIENT shall be the sole owner of all the rights to such Works in any form and
in all fields of use known or hereafter existing. Upon the request of CLIENT,
and at CLIENT's sole expense, SHS will assist CLIENT in documenting or
perfecting CLIENT's ownership of the Works. Notwithstanding the foregoing,
intellectual property owned by or licensed to SHS prior to the issuance of any
task order, and which is used by SHS to develop any Works, shall remain the
property of SHS (the "Components"). CLIENT agrees not to assert against SHS and
its licensees any ownership interest in the Components. Notwithstanding the
foregoing, CLIENT shall have a non-exclusive, irrevocable, perpetual,
non-transferable (except to affiliates and to other persons CLIENT transfers or
authorizes to use the Works), worldwide, royalty-free license to use such
Components in conjunction with the Works and any subsequent versions or
derivative Works thereof. Upon the termination of this Agreement, SHS shall
return to CLIENT all Works.

                                     -6-A1-6-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/ Illegible                    /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                     -7-A1-7-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                  SCHEDULE A-1B
                                     REPORTS

      The Reports required under the Agreement to which Schedule A-1 (including
this A-1B) is attached are:

<TABLE>
<CAPTION>
Report               By Whom             Frequency           Other Information
------               -------             ---------           -----------------
<S>                  <C>                 <C>                 <C>
[***]                [***]               [***]               [***]
</TABLE>

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/ Illegible                    /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                    -1-A1B-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                  SCHEDULE A-1C
                            PREFERRED HIRING PROFILE

Qualifiers

Must have:  [***]
                  [***]
                  [***]
                  [***]
                  [***]

Business Experience Preferences

Most preferable to least preferable:

            [***]
            [***]
            [***]
            [***]

Professional Skills

Desired:    [***]
            [***]
            [***]
            [***]
            [***]
            [***]
            [***]
            [***]
            [***]
            [***]
            [***]

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/ Illegible                    /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                    -1-A1C-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                  SCHEDULE A-1E
                         MEETINGS INCLUDED IN AGREEMENT

      (indicate number; type, whether national, regional or district, and length
of training and sales meetings; also indicate the party responsible for the
costs incurred in attending)

                                             Party Responsible for Costs

      [***]                                  [***]

      Other Meetings, as requested by CLIENT CLIENT

      See the Summary of Services, Expenses, Expense Responsibility and
Reimbursement attached to the Agreement for information concerning CLIENT
responsibility for costs.

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/ Illegible                   /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                    -1-A1E-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                  SCHEDULE A-1F
                              CALL REPORTING SYSTEM

The Call reporting system to be used is:

      [***]

                  [***]

                  [***]

      [***]

                  [***]

                  [***]

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/ Illegible                   /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                    -1-A1F-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                  SCHEDULE A-3
                        SCOPE OF SERVICES - MANUAL DESIGN

      [***]

      [***]

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/ Illegible                   /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                     -1-A3-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   SCHEDULE B
           COMPENSATION - FIXED FEES, VARIABLE FEES AND FINDER'S FEES

FIXED FEES

      CLIENT shall pay SHS Fixed Fees (subject to reduction in the part of the
Term ending May 14, 2000) as follows:

      1.    For so much of the Term as ends May 14, 2000 [***] payable as
            follows:

            (i)   [***] by April 14, 1999
                        [***] by May 1, 1999
                        [***] by June 1, 1999

            (ii)  [***] per month beginning June 1, 1999

Subject, however, to reduction as follows:

      SHS will conduct [***].

      Number of Sales
      Representatives hired  Amount of
      for First Class        Reduction
      ---------------        ---------
      [***]                  [***]
      [***]                  [***]
      [***]                  [***]
      [***]                  [***]

      Number of Sales
      Representatives hired  Amount of
      for Second Class       Reduction
      ----------------       ---------
      [***]                  [***]
      [***]                  [***]

      2.    [***]

[***]

VARIABLE FEES

      [***]

      [***]

      [***]

                                     -1-B-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

Percent of Forecast           Percent of Available
Achieved                      Amount of Payment
-------------------------     -------------------------
[***]                         [***]
[***]                         [***]
[***]                         [***]
[***]                         [***]
[***]                         [***]
[***]                         [***]

                                     -2-B-2-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

FINDER'S FEES

      [***]

             Employed by            Finder's Fee and
             CLIENT                 Other Consequence
             --------------------   --------------------

             [***]                  [***]

             [***]                  [***]
                                          [***]

             [***]                  [***]
                                          [***]

             [***]                  [***]

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/ Illegible                   /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                     -3-B-3-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                   SCHEDULE C
                             INSURANCE REQUIREMENTS

      SHS shall maintain the following insurance during the Term of the
Agreement to which this Schedule is attached:

      [***]                             [***]
      [***]                             [***]

      [***]                             [***]
      [***]                             [***]

      [***]                                   [***]
      [***]                             [***]
                                                    [***]

      SHS will provide CLIENT with evidence of SHS's insurance. SHS will name
CLIENT as an additional insured party under SHS's insurance policy, and will
provide to CLIENT at least thirty (30) days prior, written notice of any change
or cancellation to the SHS's insurance program.

CLIENT:

      CLIENT shall maintain the following insurance or self-insurance during the
Term of the Agreement to which this Schedule is attached:

      [***]

                                     -1-C-1-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      CLIENT will provide SHS with evidence of CLIENT's insurance. CLIENT will
name SHS as an additional insured party under CLIENT's insurance policy, and
will provide to SHS at least thirty (30) days prior, written notice of any
change or cancellation to the CLIENT's insurance program.

         Date:  8/31/99                   Date:  9/2/99
              ---------------------             ---------------------

          /s/  Illegible                  /s/ Emory V. Anderson
         --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                       -2-

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                 FIRST AMENDMENT
                                       TO
                                SERVICE AGREEMENT

      This first amendment ("First Amendment") made as of March 8, 2002, by and
between VENTIV HEALTH U.S. SALES INC., (formerly known as Snyder Healthcare
Sales, Inc.), a New Jersey corporation ("VHS") and ADEZA BIOMEDICAL CORPORATION,
a Delaware corporation ("CLIENT") to a certain Service Agreement made as of
March 31, 1999 (the "Agreement") by and between VHS and CLIENT.

                                   WITNESSETH:

      WHEREAS, Snyder Healthcare Sales, Inc. changed is corporate name in 1999
to Ventiv Health U.S. Sales, Inc.; and

      WHEREAS, the Agreement by its terms expires May 14, 2001; and

      WHEREAS, VHS and CLIENT desire to amend and extend the Agreement as set
forth in this First Amendment.

      NOW THEREFORE, in consideration of the premises and other good and
valuable consideration, the receipt and adequacy of which is hereby
acknowledged, it is agreed as follows:

1.    Wherever "Snyder Healthcare Sales, Inc." appears in the Agreement that
      text shall be amended and deemed to read "Ventiv Health U.S. Sales, Inc."
      and wherever "SHS" appears in the Agreement that text shall be amended and
      deemed to read "VHS".

2.    The Term of the Agreement shall be extended until May 14, 2003, unless
      earlier terminated as provided in the Agreement.

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

3.    The Summary of Services in the Agreement shall be amended effective May
      15, 2001 by the Amended Summary of Services attached hereto as Exhibit A.

4.    The definition "National Business Director" on Schedule A-1 shall be
      replaced effective May 15, 2001 with "Specialty Business Unit" which means
      the [***]. The definition "Reports" on Schedule A-1 shall be amended to
      read:

            [***].

5,    The paragraph in Schedule A-1 under the heading "CLIENT SERVICES MANAGER"
      shall be deleted from the Agreement effective May 15, 2001. This function
      is included in the services provided by the Specialty Business Unit.

6.    Schedule A-1B shall be amended effective May 15, 2001 by the Amended
      Schedule A-1B attached hereto as Exhibit B.

7.    Schedule A-1F shall be deleted from the Agreement effective May 15, 2001;
      VHS will not provide Call Reports from a Call Reporting System. Instead
      VHS shall file period Sales Reports with CLIENT.

8.    Schedule A-3 concerning Manual Design shall be deleted from the Agreement
      effective May 15, 2001; those services have been completed.

9.    Schedule B in the Agreement shall be amended effective May 15, 2001 by the
      Amended Schedule B attached hereto as Exhibit C.

10.   Except as expressly amended or revised by this First Amendment the
      Agreement shall remain in full force and effect.

                                        2

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      WHEREFORE, the parties hereto have caused this First Amendment to be
executed by their duly authorized representatives.

                                    VENTIV HEALTH U.S. SALES, INC.

                                    By:  /s/ Patrick Fourteau
                                         -----------------------------
                                         Name:  Patrick Fourteau
                                         Title:  President
                                         Dated: 3/14/02

                                    ADEZA BIOMEDICAL CORPORATION

                                    By:  /s/ Emory V. Anderson
                                         -----------------------------
                                         Name:  Emory V. Anderson
                                         Title:  President and CEO
                                         Dated: 3/8/02

                                        3

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                                                       Exhibit A

                      AMENDED SUMMARY OF SERVICES, EXPENSES
                    EXPENSE RESPONSIBILITY AND REIMBURSEMENTS

      VHS and CLIENT agree to the following Services, Expenses, Expense
Responsibility and Reimbursement obligations set out under headings in alpha
order. CLIENT shall promptly reimburse VHS (including reimbursement for the
reasonable expenses of individuals employed by VHS or provided by VHS to perform
the Scope of Services under the Agreement to which this Schedule is attached)
for the reasonable cost of the following items listed below under the heading
"VHS Passthrough Expense to CLIENT":

--------------------------------------------------------------------------------
CATEGORY                 CLIENT           VHS PASSTHROUGH        INCLUDED IN
                         EXPENSE          EXPENSE TO CLIENT      VHS FEE
--------------------------------------------------------------------------------
ADMINISTRATIVE           [***]            [***]                  [***]
Business Cards
Photocopies
Office Supplies
Phone
Postage
Printing
Stationary
Overnight Courier
Other
--------------------------------------------------------------------------------
ANALYTICS/HPR            [***]            [***]                  [***]
Alignment
Call Plan
ROI Analysis
Other
--------------------------------------------------------------------------------
AUTO COSTS               [***]            [***]                  [***]
Mileage
Parking
Tolls
Other
--------------------------------------------------------------------------------

                                       A-1

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

--------------------------------------------------------------------------------
CATEGORY                 CLIENT           VHS PASSTHROUGH        INCLUDED IN
                         EXPENSE          EXPENSE TO CLIENT      VHS FEE
--------------------------------------------------------------------------------
BENEFITS                 [***]            [***]                  [***]
Medical
Dental
401(k)
Other
--------------------------------------------------------------------------------
BILLABLE CALLS           [***]            [***]                  [***]
(Hrs) Projected
Group Calls
--------------------------------------------------------------------------------
BONUS INCENTIVES         [***]            [***]                  [***]
VHS
Managers
Representatives
Client Serv
Other
--------------------------------------------------------------------------------
CLIENT OVERHEAD          [***]            [***]                  [***]
--------------------------------------------------------------------------------
CONFERENCE CALLS         [***]            [***]                  [***]
--------------------------------------------------------------------------------
EQUIPMENT                [***]            [***]                  [***]
Computer
Detail Bags
Faxes
Printer
Other
--------------------------------------------------------------------------------
INSURANCE                [***]            [***]                  [***]
Auto
Employment
Liability
Life
Travel
Workers Comp
Other
--------------------------------------------------------------------------------
MAILOUT                  [***]            [***]                  [***]
Correspondence
Materials
Samples
Other
--------------------------------------------------------------------------------
MARKETING                [***]            [***]                  [***]
--------------------------------------------------------------------------------

                                       A-2

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

--------------------------------------------------------------------------------
CATEGORY                 CLIENT           VHS PASSTHROUGH        INCLUDED IN
                         EXPENSE          EXPENSE TO CLIENT      VHS FEE
--------------------------------------------------------------------------------
MEETINGS                 [***]            [***]                  [***]
Client
Launch
Manager
Medical
Nat'l
POA
Training
Others
--------------------------------------------------------------------------------
NATIONAL BUSINESS        [***]            [***]                  [***]
DIRECTOR
Full/Part Time
--------------------------------------------------------------------------------
OTHER SERVICES           [***]            [***]                  [***]
--------------------------------------------------------------------------------
PROMOTIONAL              [***]            [***]                  [***]
Entertainment
Gifts
Meals
Programs
Other
--------------------------------------------------------------------------------
RECRUITING               [***]            [***]                  [***]
Ads
Interviews
Referrals
Reference checks, screens
Ride alongs
Other
--------------------------------------------------------------------------------
REPORTING SYSTEM         [***]            [***]                  [***]
Paper Based
Back Up
Automated

------------
(type)
--------------------------------------------------------------------------------
SALARIES/WAGES           [***]            [***]                  [***]
Managers
Reps
Client Services
Other
--------------------------------------------------------------------------------

                                       A-3

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

--------------------------------------------------------------------------------
CATEGORY                 CLIENT           VHS PASSTHROUGH        INCLUDED IN
                         EXPENSE          EXPENSE TO CLIENT      VHS FEE
--------------------------------------------------------------------------------
SALES MATERIALS          [***]            [***]                  [***]
--------------------------------------------------------------------------------
SALES REPRESENTATIVES    [***]            [***]                  [***]
--------------------------------------------------------------------------------
Number
Full/Flex time
Dedicated/
  Syndicated
--------------------------------------------------------------------------------
SALES REPORTS            [***]            [***]                  [***]
--------------------------------------------------------------------------------
SAMPLES                  [***]            [***]                  [***]
--------------------------------------------------------------------------------
SEVERANCE                [***]            [***]                  [***]
--------------------------------------------------------------------------------
VHS OVERHEAD             [***]            [***]                  [***]
--------------------------------------------------------------------------------
SPECIAL CLIENT REQUESTS  [***]            [***]                  [***]
--------------------------------------------------------------------------------
STAFFING SERVICES        [***]            [***]                  [***]
Number of Persons
Type of Event
Location
Dates
--------------------------------------------------------------------------------
TARGETS                  [***]            [***]                  [***]
Physician
Specialty(ies)
PA's/NP's
Pharmacists
Hospitals
Clinics
Managed Care
Entity
--------------------------------------------------------------------------------
TAXES                    [***]            [***]                  [***]
Payroll
(FICA,...)
Other
--------------------------------------------------------------------------------

                                       A-4

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

--------------------------------------------------------------------------------
CATEGORY                 CLIENT           VHS PASSTHROUGH        INCLUDED IN
                         EXPENSE          EXPENSE TO CLIENT      VHS FEE

--------------------------------------------------------------------------------
TRAINING                 [***]            [***]                  [***]
Manager
Rep
Home Study
Initial Training
Advanced Training
Computer
Selling Skills
Training
Materials
Other
--------------------------------------------------------------------------------
TRAVEL EXPENSES          [***]            [***]                  [***]
Air
Auto
Hotel
Meals
Shuttle/Taxi
Tips
Incidentals
Other
--------------------------------------------------------------------------------
VOICE MAIL               [***]            [***]                  [***]
--------------------------------------------------------------------------------
ALL OTHER FIELD EXPENSE  [***]            [***]                  [***]
--------------------------------------------------------------------------------

                                       A-5

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

     TERMS OF AGREEMENT
--------------------------------------------------------------------------------
TERM                                                 Date
Start Date                                           May 15, 2001
End/Renew Date                                       May 14, 2003
--------------------------------------------------------------------------------

         Date:  3/14/02                   Date:  3/8/02
              ---------------------             ---------------------

          /s/ Patrick Fourteau            /s/ Emory V. Anderson
        --------------------------       ---------------------------
         Authorized SHS Person            Authorized CLIENT Person

                                       A-6

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                                                       Exhibit B

                              AMENDED SCHEDULE A-1B
                                     REPORTS

         The Reports required under the Agreement to which Schedule A-1
(including this A-1B) is attached are:

     Report              By Whom           Frequency           Other Information

[***]                 [***]              [***]                 [***]

Date:       3/14/02                             Date:       3/8/02
     --------------------                            --------------------

/s/ Illegible                                   /s/ Emory V. Anderson
-------------------------                       -------------------------
Authorized VHS Person                           Authorized CLIENT Person

                                    A-1B-1

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                                                       Exhibit C

                               AMENDED SCHEDULE B
           COMPENSATION - FIXED FEES, VARIABLE FEES AND FINDER'S FEES

FIXED FEES

         CLIENT shall pay VHS Fixed Fees as follows:

for the period May 15, 2001 to May 14, 2002
-------------------------------------------
         [***]

for the Period May 15, 2002 to Mgy 14, 2003
-------------------------------------------
         [***]

VARIABLE FEES

         [***]

                          Adeza-Ventiv Risk Share Pool

RISK POOL CRITERIA

[***]

[***]
[***]

Sales Targets (Pool A)

PERFORMANCE                     PAYOUT

[***]                           [***]
[***]                           [***]
[***]                           [***]
[***]                           [***]
[***]                           [***]

Non-Sales Performance

GOAL                                      PAYOUT

[***]                                     [***]

                                       B-1

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

[***]                                     [***]

Example

[***]

PERFORMANCE                                PAYOUT

[***]                                      [***]
[***]                                      [***]

[***]                                      [***]
[***]

                                       B-2

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

FINDERS' FEES

         [***]

Date:       3-14-02                             Date:       3/8/02
     --------------------                            --------------------

/s/ Illegible                                   /s/ Emory V. Anderson
-------------------------                       -------------------------
Authorized VHS Person                           Authorized CLIENT Person

                                       B-3

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                SECOND AMENDMENT
                                       TO
                                SERVICE AGREEMENT

      This second amendment ("Second Amendment") made as of July 22, 2002, by
and between VENTIV HEALTH U.S. SALES LLC, a New Jersey limited liability company
and successor by merger to Ventiv Health U.S. Sales, Inc., A New Jersey
corporation ("VHS') and ADEZA BIOMEDICAL CORPORATION, a Delaware corporation
("CLIENT') to a certain Service Agreement made as of March 31, 1999 (the
"Agreement') by and between VHS and CLIENT and previously amended by a certain
First Amendment made as of March 8, 2001 (the "First Amendment", the Agreement
as so amended being the "Amended Agreement") by and between VHS and CLIENT.

                                   WITNESSETH:

      WHEREAS, the Amended Agreement by its terms expires May 14, 2003; and

      WHEREAS, VHS and CLIENT desire to amend the Agreement to add a second
field force of VHS personnel (the "Direct Force"; the original field force of
VHS personnel being the "General Force") and to extend the Agreement as set
forth in this Second Amendment.

      NOW THEREFORE, in consideration of the premises and other good and
valuable consideration, the receipt and adequacy of which is hereby
acknowledged, it is agreed as follows:

1.    Wherever "Ventiv Health U.S. Sales, Inc." appears in the Amended Agreement
      that text shall be amended and deemed to read "Ventiv Health U.S. Sales
      LLC".

2.    The Term of the Agreement shall be extended until May 14, 2004, unless
      earlier terminated as provided in the Agreement.

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

3.    The Summary of Services in the Agreement shall be amended effective May
      15, 2002 by the Second Amended Summary of Services attached hereto as
      Exhibit A.

4.    The text of Schedule A-1 in this Agreement under the headings "HIRE STATUS
      AND

      WORK SCHEDULE" and "CALLS AND TARGETS" is replaced in its entirety by the
      following:

      HIRE STATUS AND WORK SCHEDULE

                  [***]

                  [***]

                  [***]

      CALLS AND TARGETS

                  [***]

                  [***]

5.    The heading "CALL ACTIVITY" in Schedule A-1 and the text thereunder are
      deleted and the heading "SALES FORCE STATUS" is revised to read "STATUS OF
      SALES FORCES."

6.    Schedule B in the Agreement shall be amended effective May 15, 2002 by the
      Second Amended Schedule B attached hereto as Exhibit B.

                                       2

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

7.    Except as expressly amended or revised by this First Amendment the
      Agreement shall remain in full force and effect.

                                       3

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

      WHEREFORE, the parties hereto have caused this First Amendment to be
      executed by their duly authorized representatives.

                                                VENTIV HEALTH U.S. SALE LLC

                                                By:  /s/ Terrell G. Herring
                                                   ------------------------
                                                   Name: Terrell G. Herring
                                                   Title: President
                                                   Dated: July 24, 2002

                                                ADEZA BIOMEDICAL CORPORATION

                                                By:  /s/ Emory V. Anderson
                                                   ------------------------
                                                   Name: Emory V. Anderson
                                                   Title: President and CEO
                                                   Dated: July 22, 2002

                                       4

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED
                                                                       Exhibit A

                  SECOND AMENDED SUMMARY OF SERVICES, EXPENSES
                    EXPENSE RESPONSIBILITY AND REIMBURSEMENTS

         VHS and CLIENT agree to the following Services, Expenses, Expense
Responsibility and Rcimbursement obligations set out under headings in alpha
order. CLIENT shall promptly reimburse VHS (including reimbursement for the
reasonable expenses of individuals employed by VHS or provided by VHS to perform
the Scope of Services under the Agreement to which this Schedule is attached)
for the reasonable cost of the following items listed below under the heading
"VHS Passthrough Expense to CLIENT":

<TABLE>
<CAPTION>
CATEGORY                             CLIENT          VHS PASSTHROUGH        INCLUDED IN
                                     EXPENSE         EXPENSE TO CLIENT      VHS FEE
<S>                                  <C>             <C>                    <C>
ADMINISTRATIVE                       [***]           [***]                  [***]
Business Cards
Photocopies
Office Supplies
Phone
Postage
Printing
Stationary
Overnight Courier
Other
ANALYTICS/HPR                        [***]           [***]                  [***]
Alignment
Call Plan
ROI Analysis
Other
</TABLE>
                                      A-5

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

<TABLE>
<CAPTION>
CATEGORY                             CLIENT          VHS PASSTHROUGH        INCLUDED IN
                                     EXPENSE         EXPENSE TO CLIENT      VHS FEE
<S>                                  <C>             <C>                    <C>
AUTO COSTS                           [***]           [***]                  [***]
Mileage
Parking
Tolls
Other
BENEFITS                             [***]           [***]                  [***]
Medical
Dental
401(k)
Other
BILLABLE CALLS                       [***]           [***]                  [***]
(Hrs) Projected
Group Calls
BONUS INCENTIVES                     [***]           [***]                  [***]
VHS
Managers
Representatives
Client Serv
Other
CLIENT OVERHEAD                      [***]           [***]                  [***]

CONFERENCE CALLS                     [***]           [***]                  [***]

EQUIPMENT                            [***]           [***]                  [***]
Computer
Detail Bags
Faxes
Printer
Other
INSURANCE                            [***]           [***]                  [***]
Auto
Employment
Liability
Life
Travel
Workers Comp
Other
MAILOUT                              [***]           [***]                  [***]
Correspondence
Materials
Samples
Other
MARKETING                            [***]           [***]                  [***]
</TABLE>

                                      A-6

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

<TABLE>
<CAPTION>
CATEGORY                             CLIENT          VHS PASSTHROUGH        INCLUDED IN
                                     EXPENSE         EXPENSE TO CLIENT      VHS FEE
<S>                                  <C>             <C>                    <C>
MEETINGS                             [***]           [***]                  [***]
Client
Launch
Manager
Medical
Nat'l
POA
Training
Others
NATIONAL BUSINESS DIRECTOR           [***]           [***]                  [***]
Full/Part Time

OTHER SERVICES                       [***]           [***]                  [***]

PROMOTIONAL                          [***]           [***]                  [***]
Entertainment
Gifts
Meals
Programs
Other
RECRUITING                           [***]           [***]                  [***]
Ads
Interviews
Referrals
Reference checks, screens
Ride alongs
Other
REPORTING SYSTEM                     [***]           [***]                  [***]
Paper Based
Back Up
Automated
______________
(type)
SALARIES/WAGES                       [***]           [***]                  [***]
Managers
Reps
Client Services
Other
SALES MATERIALS                      [***]           [***]                  [***]

SALES REPRESENTATIVES                [***]           [***]                  [***]
Number
Full/Flex time
</TABLE>

                                      A-7

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

<TABLE>
<CAPTION>
CATEGORY                             CLIENT          VHS PASSTHROUGH        INCLUDED IN
                                     EXPENSE         EXPENSE TO CLIENT      VHS FEE
<S>                                  <C>             <C>                    <C>
Dedicated/
  Syndicated
SALES REPORTS                        [***]           [***]                  [***]
SAMPLES                              [***]           [***]                  [***]

SEVERANCE                            [***]           [***]                  [***]
VHS OVERHEAD                         [***]           [***]                  [***]

SPECIAL CLIENT REQUESTS              [***]           [***]                  [***]

STAFFING SERVICES                    [***]           [***]                  [***]
Number of Persons
Type of Event
Location
Dates
TARGETS                              [***]           [***]                  [***]
Physician
Specialty(ies)
PA's/NP's
Pharmacists
Hospitals
Clinics
Managed Care
Entity
TAXES                                [***]           [***]                  [***]
Payroll
(FICA,...)
Other
</TABLE>

                                      A-8

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

<TABLE>
<CAPTION>
CATEGORY                             CLIENT          VHS PASSTHROUGH        INCLUDED IN
                                     EXPENSE         EXPENSE TO CLIENT      VHS FEE
<S>                                  <C>             <C>                    <C>
TRAINING                             [***]           [***]                  [***]
Manager
Rep
Home Study
Initial Training
Advanced Training
Computer
Selling Skills
Training
Materials
Other
TRAVEL EXPENSES                      [***]           [***]                  [***]
Air
Auto
Hotel
Meals
Shuttle/Taxi
Tips
Incidentals
Other
VOICE MAIL                           [***]           [***]                  [***]

ALL OTHER FIELD EXPENSE              [***]           [***]                  [***]
</TABLE>

                TERMS OF AGREEMENT

<TABLE>
<CAPTION>
TERM                                                  Date
<S>                                                   <C>
Start Date                                            May 15, 2002
End/Renew Date                                        May 14, 2004
</TABLE>

Date:       7/23/02                             Date:    July 22, 2002
     --------------------                            --------------------

/s/ Terrell G. Herring                          /s/ Emory V. Anderson
-------------------------                       -------------------------
Authorized VHS Person                           Authorized CLIENT Person

                                       A-9

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED
                                                                       Exhibit B

                            SECOND AMENDED SCHEDULE B
           COMPENSATION - FIXED FEES, VARIABLE FEES AND FINDER'S FEES

FIXED FEES

         CLIENT shall pay VHS Fixed Fees as follows:

A.       For the Wave I Force:
         --------------------

1.       For the period May 15, 2001 to May 14, 2002
         -------------------------------------------

         [***]

2.       For the period May 15, 2002 to May 14, 2003
         -------------------------------------------

         [***]

3.       For the period May 15, 2003 to May 14, 2004
         -------------------------------------------

         [***]

B.       For the Wave II Force 1.
         -----------------------

1.       For the period May 15, 2002 to May 14, 2003
         -------------------------------------------

         [***]

2.       For the period May 15, 2003 to May 14, 2004
         -------------------------------------------

         [***]

VARIABLE FEES

         [***]

                                      B-2

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

FINDERS' FEES

         [***]

Date:       7/23/02                             Date:    July 22, 2002
     --------------------                            --------------------

/s/ Terrell G. Herring                          /s/ Emory V. Anderson
-------------------------                       -------------------------
Authorized VHS Person                           Authorized CLIENT Person

                                      B-3

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED
                                                                       Exhibit B

                          Adeza-Ventiv Risk Share Pool

RISK POOL CRITERIA

Through May 14, 2003

[***]

[***]
[***]

Through May 15, 2003

[***]

[***]
[***]

Sales Targets (Pool A)

PERFORMANCE                                 PAYOUT

[***]                                       [***]
[***]                                       [***]
[***]                                       [***]
[***]                                       [***]
[***]                                       [***]

Non-Sales Performance

GOAL                                                      PAYOUT

[***]                                                     [***]

[***]                                                     [***]

Example (computed prior to May 15, 2003)

[***]

                                      B-3

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

                                 THIRD AMENDMENT
                                       TO
                                SERVICE AGREEMENT

      This third amendment ("Third Amendment") made as of May 15, 2004, by and
between VENTIV HEALTH U.S. SALES LLC, a New Jersey limited liability company
("VHS") and ADEZA BIOMEDICAL CORPORATION, a Delaware corporation ("CLIENT"`) to
a certain Service Agreement made as of March 31, 1999 (the "Agreement") by and
between VHS and CLIENT, as amended by a First Amendment made as of March 8, 2001
(the "First Amendment") and a Second Amendment made as of July 22, 2002 (the
"Second Amendment").

                                   WITNESSETH:

      WHEREAS, on or about February 2, 2004, VHS commenced providing sales force
automation services to CLIENT.

      WHEREAS, VHS and CLIENT desire to further amend the Agreement by extending
the term and changing the [***] as set forth in this Third Amendment (the
Agreement as amended by the First Amendment, Second Amendment and this Tbird
Amendment referred to herein as the "Amended Agreement").

      NOW THEREFORE, in consideration of the premises and other good and
valuable consideration, the receipt and adequacy of which is hereby
acknowledged, it is agreed as follows:

1. Construction. All terms not otherwise defined in this Amendment shall have
the meanings set forth in the Amended Agreement. Except as set forth herein, the
Amended Agreement shall remain unaffected by execution of this Third Amendment.

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

2. The Extended Term. The Term of the Amended Agreement shall be extended until
May 14, 2006 (the "Extended Term"), unless earlier terminated as provided in the
Amended Agreement.

3. The Fixed Fess payable by CLIENT to VHS during the Extended Term, as set
forth in Exhibit B attached to the Second Amendment ("Second Amended Schedule B,
Compensation -Fixed Fees, Variable Fees and Finder's Fees), are revised to
provide for the payment of the following Fixed Fees from CLIENT to VHS:

<TABLE>
<CAPTION>
         PERIOD                   YEARLY COST PER
                                       SALES                     YEARLY COST PER
                                   REPRESENTATIVE               DISTRICT MANAGER
<S>                               <C>                           <C>
     May 15, 2004 -                    [***]                          [***]

     May 15, 2005 -                    [***]
      May 14, 2006                                                    [***]
</TABLE>

4. The Variable Fees payable by CI.JFNT to VHS during the Extended Term are as
follows: [***].

5. Schedule A-1F Call Reporting System shall be replaced by the First Amendcd
Schedule A-1F attached to this Third Amendment as Exhibit I. [***].

6. Representatives must be provided with internet service [***].

7. In the event of termination of the Amended Agreement in accordance with
Sections 10.1 or Section 10.2, or at the end of the Extended Term, CLIENT shall
be [***].

                                        2

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED

8. In the event a Sales Representative is terminated (voluntarily or
involuntarily), VHS shall [***].

9. If CLIENT converts any or all Sales Representatives, [***].

10 Notwithstanding anything to the contrary set forth in this Amended Agreement
all office supplies, printing, postage, costs associated with phone service, in
addition to all travel costs, Sales Representative and District Manager bonuses
(including employer portion of travel), and marketing funds will be [***].

11. All references in the Amended Agreement to a maximum number of Sales
Representatives or District Managers are hereby removed, it being understood
that the CLIENT and VHS may agree, in writing, to increase the number of VHS
employees providing services under the Amended Agreement.

      WHEREFORE, the parties hereto have caused this Third Amendment to be
executed by their duly authorized representatives.

                                       VENTIV HEALTH U.S. SALE LLC

                                       By:  /s/ Terrell G. Herring
                                          ------------------------
                                       Name: Terrell G. Herring
                                       Title: President
                                       Dated: 7/29/04

                                       ADEZA BIOMEDICAL CORPORATION

                                       By:  /s/ Emory V. Anderson
                                          ------------------------
                                          Name: Emory V. Anderson
                                          Title: President and CEO
                                          Dated: 7/27/04

                                        3

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.

<PAGE>
                                                CONFIDENTIAL TREATMENT REQUESTED
                                                                       Exhibit I

                           First Amended SCHEDULE A-IF
                              CALL REPORTING SYSTEM

      The Call Reporting system to be used is hand held solution (does not
include laptops) that is:

                  [***]
                               [***]
                               [***]

Date:       7/29/04                             Date:    7/27/04
     --------------------                            --------------------

/s/ Terrell G. Herring                          /s/ Emory V. Anderson
-------------------------                       -------------------------
Authorized VHS Person                           Authorized CLIENT Person

                                     A1F-1

THE SYMBOL [***] IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.<PAGE>

                                                                    EXHIBIT 10.9

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED
WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION
OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH
REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE
APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE
PROVISIONS OF SECTION 7 OF THIS WARRANT.

                          ADEZA BIOMEDICAL CORPORATION

                           WARRANT TO PURCHASE SHARES
                           OF SERIES 3 PREFERRED STOCK

      THIS CERTIFIES THAT, for value received, TRANSAMERICA BUSINESS CREDIT
CORPORATION and its assignees are entitled to subscribe for and purchase the
number of shares set forth in the next paragraph of the fully paid and
nonassessable Series 3 Preferred Stock (as adjusted pursuant to Section 4
hereof, the "Shares") of ADEZA BIOMEDICAL CORPORATION, a Delaware corporation
(the "Company"), at the price of $2.92 per share, which is equivalent to $2.628
per share on an as-converted-to-Common Stock basis (such price and such other
price as shall result, from time to time, from the adjustments specified in
Section 4 hereof is herein referred to as the "Warrant Price"), subject to the
provisions and upon the terms and conditions hereinafter set forth.
Notwithstanding the foregoing, if on or before July 31, 1999, (a) the Company
enters into a corporate partnering arrangement having proceeds of at least
$3,000,000 and, in addition, closes a Qualified Financing having net proceeds to
the Company of not less than $3,000,000, or (b) a Qualified Financing having net
proceeds to the Company of not less than $6,000,000, the Warrant Price shall be
the average of (i) $2.92 and (ii) the price per share (on a common stock
equivalent basis) at which shares of the Company's convertible preferred stock
are sold in such Qualified Financing, multiplied by a fraction (the
"Multiplier"), the numerator of which shall be $2.92 and the denominator of
which shall be the then-current "Series 3 Conversion Price" as set forth in the
Company's Charter (as defined below); provided, however, that if the price per
share (on a common stock equivalent basis) at which shares of the Company's
convertible preferred stock are sold in such Qualified Financing is less than
$2.628 per share, then the Warrant Price shall be such lesser price per share
multiplied by the Multiplier. A "Qualified Financing" shall mean the sale of the
convertible preferred stock of the Company to purchasers which include venture
capital investors.

      The number of shares for which this Warrant is exercisable shall be the
nearest whole number determined by dividing $300,000 by the Warrant Price
determined pursuant to the previous paragraph. Notwithstanding the foregoing
sentence, if the initial holder of this Warrant has not made available a loan in
the amount of $1,000,000 under Facility C of the Loan and Security Agreement,
dated as of March 19, 1999, among the initial holder of this Warrant, MMC/GATX
Partnership No. I and foe Company on or prior to December 31, 1999, men the
number of shares for which this Warrant is exercisable shall be the nearest
whole number determined by dividing $170,000 by the Warrant Price determined
pursuant to the previous paragraph.

      As used herein, (a) the term "Series Preferred" shall mean the Company's
presently authorized Series 3 Preferred Stock, and any stock into or for which
such Series 3 Preferred Stock may hereafter be converted or exchanged, and after
the automatic conversion of the Series 3 Preferred Stock to

<PAGE>

Common Stock shall mean the Company's Common Stock, (b) the term "Date of Grant"
shall mean March 23, 1999, and (c) the term "Other Warrants" shall mean any
other warrants issued by the Company in connection with the transaction with
respect to which this Warrant was issued, and any warrant issued upon transfer
or partial exercise of or in lieu of this Warrant. The term "Warrant" as used
herein shall be deemed to include Other Warrants unless the context clearly
requires otherwise.

      1.    Term. The purchase right represented by this Warrant is exercisable,
in whole or in part, at any time and from time to time from the Date of Grant
through the later of (i) ten (10) years after the Date of Grant or (ii) five (5)
years after the closing of the Company's initial public offering of its Common
Stock effected pursuant to a Registration Statement on Form S-1 (or its
successor) filed under the Securities Act of 1933, as amended (the "Act"), but
in no event longer than fifteen (15) years from the Date of Grant.

      2.    Method of Exercise; Payment; Issuance of New Warrant. Subject to
Section 1 hereof, the purchase right represented by mis Warrant may be exercised
by the holder hereof, in whole or in part and from time to time, at the election
of the holder hereof, by (a) the surrender of this Warrant (with the notice of
exercise substantially in the form attached hereto as Exhibit A-1 duly completed
and executed) at the principal office of the Company and by the payment to the
Company, by certified or bank check, or by wire transfer to an account
designated by the Company (a "Wire Transfer") of an amount equal to the then
applicable Warrant Price multiplied by the number of Shares then being
purchased; (b) if in connection with a registered public offering of the
Company's securities, the surrender of this Warrant (with the notice of exercise
form attached hereto as Exhibit A-2 duly completed and executed) at the
principal office of the Company together with notice of arrangements reasonably
satisfactory to the Company for payment to the Company either by certified or
bank check or by Wire Transfer from the proceeds of the sale of shares to be
sold by the holder in such public offering of an amount equal to the then
applicable Warrant Price per share multiplied by the number of Shares then being
purchased; or (c) exercise of the "net issuance" right provided for in Section
10.2 hereof. The person or persons in whose name(s) any certificate(s)
representing shares of Series Preferred shall be issuable upon exercise of this
Warrant shall be deemed to have become the holder(s) of record of, and shall be
treated for all purposes as the record holder(s) of, the shares represented
thereby (and such shares shall be deemed to have been issued) immediately prior
to the close of business on the date or dates upon which this Warrant is
exercised. In the event of any exercise of the rights represented by this
Warrant, certificates for the shares of stock so purchased shall be delivered to
the holder hereof as soon as possible and in any event within thirty (30) days
after such exercise and, unless this Warrant has been fully exercised or
expired, a new Warrant representing the portion of the Shares, if any, with
respect to which this Warrant shall not then have been exercised shall also be
issued to the holder hereof as soon as possible and in any event within such
thirty-day period.

      3.    Stock Fully Paid; Reservation of Shares. All Shares that may be
issued upon the exercise of the rights represented by this Warrant will, upon
issuance pursuant to the terms and conditions herein, be fully paid and
nonassessable, and free from all taxes, liens and charges with respect to the
issue thereof. During the period within which the rights represented by this
Warrant may be exercised, the Company will at all times have authorized, and
reserved for the purpose of the issue upon exercise of the purchase rights
evidenced by this Warrant, a sufficient number of shares of its

                                       -2-

<PAGE>

Series Preferred to provide for the exercise of the rights represented by this
Warrant and a sufficient number of shares of its Common Stock to provide for
the conversion of the Series Preferred into Common Stock.

      4.    Adjustment of Warrant Price and Number of Shares. The number and
kind of securities purchasable upon the exercise of this Warrant and the Warrant
Price shall be subject to adjustment from time to time upon the occurrence of
certain events, as follows:

            (a)   Reclassification or Merger. In case of any reclassification or
change of securities of the class issuable upon exercise of this Warrant (other
than a change in par value, or from par value to no par value, or from no par
value to par value, or as a result of a subdivision or combination), or in case
of any merger of the Company with or into another corporation (other than a
merger with another corporation in which the Company is the acquiring and the
surviving corporation and which does not result in any reclassification or
change of outstanding securities issuable upon exercise of this Warrant), or in
case of any sale of all or substantially all of the assets of the Company, the
Company, or such successor or purchasing corporation, as the case may be, shall
duly execute and deliver to the holder of this Warrant a new Warrant (in form
and substance satisfactory to the holder of this Warrant), or the Company shall
make appropriate provision without the issuance of a new Warrant, so that the
holder of this Warrant shall have the right to receive, at a total purchase
price not to exceed that payable upon the exercise of the unexercised portion of
this Warrant, and in lieu of the shares of Series Preferred theretofore issuable
upon exercise of this Warrant, (i) the kind and amount of shares of stock, other
securities, money and property receivable upon such reclassification, change,
merger or sale by a holder of the number of shares of Series Preferred then
purchasable under this Warrant, or (ii) in the case of such a merger or sale in
which the consideration paid consists all or in part of assets other than
securities of the successor or purchasing corporation, the securities of the
successor or purchasing corporation having a value at the time of the
transaction equivalent to the valuation of the Series Preferred at the time of
the transaction. Any new Warrant shall provide for adjustments that shall be as
nearly equivalent as may be practicable to the adjustments provided for in this
Section 4. The provisions of this subparagraph (a) shall similarly apply to
successive reclassifications, changes, mergers and transfers.

            (b)   Subdivision or Combination of Shares. If the Company at any
time while this Warrant remains outstanding and unexpired shall subdivide or
combine its outstanding shares of Series Preferred, the Warrant Price shall be
proportionately decreased and the number of Shares issuable hereunder shall be
proportionately increased in the case of a subdivision and the Warrant Price
shall be proportionately increased and the number of Shares issuable hereunder
shall be proportionately decreased in the case of a combination.

            (c)   Stock Dividends and Other Distributions. If the Company at any
time while this Warrant is outstanding and unexpired shall (i) pay a dividend
with respect to Series Preferred payable in Series Preferred, then the Warrant
Price shall be adjusted, from and after the date of determination of
shareholders entitled to receive such dividend or distribution, to that price
determined by multiplying the Warrant Price in effect immediately prior to such
date of determination by a fraction (A) the numerator of which shall be the
total number of shares of Series Preferred outstanding immediately

                                       -3-

<PAGE>

prior to such dividend or distribution, and (B) the denominator of which shall
be the total number of shares of Series Preferred outstanding immediately after
such dividend or distribution; or (ii) make any other distribution with respect
to Series Preferred (except any distribution specifically provided for in
Sections 4(a) and 4(b)), then, in each such case, provision shall be made by the
Company such that the holder of this Warrant shall receive upon exercise of this
Warrant a proportionate share of any such dividend or distribution as though it
were the holder of the Series Preferred (or Common Stock issuable upon
conversion thereof) as of the record date fixed for the determination of the
shareholders of the Company entitled to receive such dividend or distribution.

            (d)   Adjustment of Number of Shares. Upon each adjustment in the
Warrant Price (under Section 4(c) above), the number of Shares of Series
Preferred purchasable hereunder shall be adjusted, to the nearest whole share,
to the product obtained by multiplying the number of Shares purchasable
immediately prior to such adjustment in the Warrant Price by a fraction, the
numerator of which shall be the Warrant Price immediately prior to such
adjustment and the denominator of which shall be the Warrant Price immediately
thereafter.

            (e)   Antidilution Rights. The other antidilution rights applicable
to the Shares of Series Preferred purchasable hereunder are set forth in the
Company's Certificate of Incorporation, as amended through the Date of Grant, a
true and complete copy of which is attached hereto as Exhibit B (the "Charter").
Such antidilution rights shall not be restated, amended, modified or waived in
any manner that is adverse to the holder hereof (in a manner that is separate
and distinct from the effect on the other holders of Series 3 Preferred Stock)
without such holder's prior written consent. The Company shall promptly provide
the holder hereof with any restatement, amendment, modification or waiver of the
Charter promptly after the same has been made.

      5.    Notice of Adjustments. Whenever the Warrant Price or the number of
Shares purchasable hereunder shall be adjusted pursuant to Section 4 hereof, the
Company shall make a certificate signed by its chief financial officer setting
forth, in reasonable detail, the event requiring the adjustment, the amount of
the adjustment, the method by which such adjustment was calculated, and the
Warrant Price and the number of Shares purchasable hereunder after giving effect
to such adjustment, and shall cause copies of such certificate to be mailed
(without regard to Section 13 hereof, by first class mail, postage prepaid) to
the holder of this Warrant. In addition, whenever the conversion price or
conversion ratio of the Series Preferred shall be adjusted, the Company shall
make a certificate signed by its chief financial officer setting forth, in
reasonable detail, the event requiring the adjustment, the amount of the
adjustment, the method by which such adjustment was calculated, and the
conversion price or ratio of the Series Preferred after giving effect to such
adjustment, and shall cause copies of such certificate to be mailed (without
regard to Section 13 hereof, by first class mail, postage prepaid) to the holder
of this Warrant.

      6.    Fractional Shares. No fractional shares of Series Preferred will be
issued in connection with any exercise hereunder, but in lieu of such fractional
shares the Company shall make a cash payment therefor based on the fair market
value of the Series Preferred on the date of exercise as reasonably determined
in good faith by the Company's Board of Directors.

                                       -4-

<PAGE>

      7.    Compliance with Act; Disposition of Warrant or Shares of Series
Preferred.

            (a)   Compliance with Act. The holder of this Warrant, by acceptance
hereof, agrees that this Warrant, and the shares of Series Preferred to be
issued upon exercise hereof and any Common Stock issued upon conversion thereof
are being acquired for investment and that such holder will not offer, sell or
otherwise dispose of this Warrant, or any shares of Series Preferred to be
issued upon exercise hereof or any Common Stock issued upon conversion thereof
except under circumstances which will not result in a violation of the Act or
any applicable state securities laws. Upon exercise of this Warrant, unless the
Shares being acquired are registered under the Act and any applicable state
securities laws or an exemption from such registration is available, the holder
hereof shall confirm in writing that the shares of Series Preferred so purchased
(and any shares of Common Stock issued upon conversion thereof) are being
acquired for investment and not with a view toward distribution or resale in
violation of the Act and shall confirm such other matters related thereto as may
be reasonably requested by the Company. This Warrant and all shares of Series
Preferred issued upon exercise of this Warrant and all shares of Common Stock
issued upon conversion thereof (unless registered under the Act and any
applicable state securities laws) shall be stamped or imprinted with a legend in
substantially the following form:

"THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION
MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO,
(ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE
COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION
LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE
COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT UNDER WHICH THESE
SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY."

      Said legend shall be removed by the Company, upon the request of a holder,
at such time as the restrictions on the transfer of the applicable security
shall have terminated. In addition, in connection with the issuance of this
Warrant, the holder specifically represents to the Company by acceptance of this
Warrant as follows:

      (1)   The holder is aware of the Company's business affairs and financial
condition, and has acquired information about the Company sufficient to reach an
informed and knowledgeable decision to acquire this Warrant. The holder is
acquiring this Warrant for its own account for investment purposes only and not
with a view to, or for the resale in connection with, any "distribution" thereof
in violation of the Act.

      (2)   The holder understands that this Warrant has not been registered
under the Act in reliance upon a specific exemption therefrom, which exemption
depends upon, among other things, the bona fide nature of the holder's
investment intent as expressed herein.

                                       -5-

<PAGE>

      (3)   The holder further understands that this Warrant must be held
indefinitely unless subsequently registered under the Act and qualified under
any applicable state securities laws, or unless exemptions from registration and
qualification are otherwise available. The holder is aware of the provisions of
Rule 144, promulgated under the Act.

      (4)   The holder is an "accredited investor" as such term is defined in
Rule 501 of Regulation D promulgated under the Act.

            (b)   Disposition of Warrant or Shares. With respect to any offer,
sate or other disposition of this Warrant or any shares of Series Preferred
acquired pursuant to the exercise of this Warrant prior to registration of such
Warrant or shares, the holder hereof agrees to give written notice to the
Company prior thereto, describing briefly the manner thereof, together with a
written opinion of such holder's counsel, or other evidence, if reasonably
satisfactory to the Company, to the effect that such offer, sale or other
disposition may be effected without registration or qualification (under the Act
as then in effect or any federal or state securities law then in effect) of this
Warrant or such shares of Series Preferred or Common Stock and indicating
whether or not under the Act certificates for this Warrant or such shares of
Series Preferred to be sold or otherwise disposed of require any restrictive
legend as to applicable restrictions on transferability in order to ensure
compliance with such law. Upon receiving such written notice and reasonably
satisfactory opinion or other evidence, the Company, as promptly as practicable
but no later than fifteen (15) days after receipt of the written notice, shall
notify such holder that such holder may sell or otherwise dispose of this
Warrant or such shares of Series Preferred or Common Stock, all in accordance
with the terms of the notice delivered to the Company. If a determination has
been made pursuant to this Section 7(b) that the opinion of counsel for the
holder or other evidence is not reasonably satisfactory to the Company, the
Company shall so notify the holder promptly with details thereof after such
determination has been made. Notwithstanding the foregoing, this Warrant or such
shares of Series Preferred or Common Stock may, as to such federal laws, be
offered, sold or otherwise disposed of in accordance with Rule 144 or 144A under
the Act, provided that the Company shall have been furnished with such
information as the Company may reasonably request to provide a reasonable
assurance that the provisions of Rule 144 or 144A have been satisfied. Each
certificate representing this Warrant or the shares of Series Preferred thus
transferred (except a transfer pursuant to Rule 144 or 144A) shall bear a legend
as to the applicable restrictions on transferability in order to ensure
compliance with such laws, unless in the aforesaid opinion of counsel for the
holder, such legend is not required in order to ensure compliance with such
laws. The Company may issue stop transfer instructions to its transfer agent in
connection with such restrictions.

            (c)   Applicability of Restrictions. Neither any restrictions of any
legend described in this Warrant nor the requirements of Section 7(b) above
shall apply to any transfer of, or grant of a security interest in, this Warrant
(or the Series Preferred or Common Stock obtainable upon exercise thereof) or
any part hereof (i) to a partner of the holder if the holder is a partnership or
to a member of the holder if the holder is a limited liability company, (ii) to
a partnership of which the holder is a partner or to a limited liability company
of which the holder is a member, or (iii) to any affiliate of the holder if the
holder is a corporation; provided, however, in any such transfer, if applicable,
the

                                       -6-

<PAGE>

transferee shall on the Company's request agree in writing to be bound by the
terms of this Warrant as if an original holder hereof.

      8.    Rights as Shareholders; Information. No holder of this Warrant, as
such, shall be entitled to vote or receive dividends or be deemed the holder of
Series Preferred or any other securities of the Company which may at any time be
issuable on the exercise hereof for any purpose, nor shall anything contained
herein be construed to confer upon the holder of this Warrant, as such, any of
the rights of a shareholder of the Company or any right to vote for the election
of directors or upon any matter submitted to shareholders at any meeting
thereof, or to receive notice of meetings, or to receive dividends or
subscription rights or otherwise until this Warrant shall have been exercised
and the Shares purchasable upon the exercise hereof shall have become
deliverable, as provided herein. Notwithstanding the foregoing, the Company will
transmit to the holder of this Warrant such information, documents and reports
as are generally distributed to the holders of any class or series of the
securities of the Company concurrently with the distribution thereof to the
shareholders.

      9.    Registration Rights. The Company grants registration rights to the
holder of this Warrant for any Common Stock of the Company obtained upon
conversion of the Series Preferred, comparable to the registration rights
granted to the investors in that certain Investor Rights Agreement dated as of
November 8, 1996 (the "Registration Rights Agreement"), with the following
exceptions and clarifications:

            (1)   The holder will have no demand registration rights.

            (2)   The holder will be subject to the same provisions regarding
                  indemnification as contained in the Registration Rights
                  Agreement.

            (3)   The registration rights are freely assignable by the holder of
                  this Warrant in connection with a permitted transfer of this
                  Warrant or the Shares.

      10.   Additional Rights.

      10.1  Acquisition Transactions. The Company shall provide the holder of
this Warrant with at least twenty (20) days' written notice prior to closing
thereof of the terms and conditions of any of the following transactions (to the
extent the Company has notice thereof): (i) the sale, lease, exchange,
conveyance or other disposition of all or substantially all of the Company's
property or business, or (ii) its merger into or consolidation with any other
corporation (other than a wholly-owned subsidiary of the Company), or any
transaction (including a merger or other reorganization) or series of related
transactions, in which more than 50% of the voting power of the Company is
disposed of.

      10.2  Right to Convert Warrant into Stock; Net Issuance.

            (a)   Right to Convert. In addition to and without limiting the
rights of the holder under the terms of this Warrant, the holder shall have the
right to convert this Warrant or any portion thereof (the "Conversion Right")
into shares of Series Preferred (or Common Stock if the Series

                                       -7-

<PAGE>

Preferred has been automatically converted into Common Stock) as provided in
this Section 10.2 at any time or from time to time during the term of this
Warrant. Upon exercise of the Conversion Right with respect to a particular
number of shares subject to this Warrant (the "Converted Warrant Shares"), the
Company shall deliver to the holder (without payment by the holder of any
exercise price or any cash or other consideration) that number of shares of
fully paid and nonassessable Series Preferred (or Common Stock if the Series
Preferred has been automatically converted into Common Stock) as is determined
according to the following formula:

      X  =  B - A
            -----
              Y

      Where:  X  =      the number of shares of Series Preferred (or Common
                        Stock if the Series Preferred has been automatically
                        converted to Common Stock) that shall be issued to
                        holder

              Y  =      the fair market value of one share of Series Preferred
                        (or Common Stock if the Series Preferred has been
                        automatically converted to Common Stock)

              A  =      the aggregate Warrant Price of the specified number of
                        Converted Warrant Shares immediately prior to the
                        exercise of the Conversion Right (i.e., the number of
                        Converted Warrant Shares multiplied by the Warrant
                        Price)

              B  =      the aggregate fair market value of the specified
                        number of Converted Warrant Shares (i.e., the number of
                        Converted Warrant Shares multiplied by the fair market
                        value of one Converted Warrant Share)

      No fractional shares shall be issuable upon exercise of the Conversion
Right, and, if the number of shares to be issued determined in accordance with
the foregoing formula is other than a whole number, the Company shall pay to the
holder an amount in cash equal to the fair market value of the resulting
fractional share on the Conversion Date (as hereinafter defined). For purposes
of Section 9 of this Warrant, shares issued pursuant to the Conversion Right
shall be treated as if they were issued upon the exercise of this Warrant.

            (b)   Method of Exercise. The Conversion Right may be exercised by
the holder by the surrender of this Warrant at the principal office of the
Company together with a written statement (which may be in the form of Exhibit
A-1 or Exhibit A-2 hereto) specifying that the holder thereby intends to
exercise the Conversion Right and indicating the number of shares subject to
this Warrant which are being surrendered (referred to in Section 10.2(a) hereof
as the Converted Warrant Shares) in exercise of the Conversion Right. Such
conversion shall be effective upon receipt by the Company of this Warrant
together with the aforesaid written statement, or on such later date as is
specified therein (the "Conversion Date"), and, at the election of the holder
hereof, may be made contingent upon the closing of the sale of the Company's
Common Stock to the public in a public offering pursuant to a

                                       -8-

<PAGE>

Registration Statement under the Act (a "Public Offering"). Certificates for the
shares issuable upon exercise of the Conversion Right and, if applicable, a new
warrant evidencing the balance of the shares remaining subject to this Warrant,
shall be issued as of the Conversion Date and shall be delivered to the holder
within thirty (30) days following the Conversion Date.

            (c)   Determination of Fair Market Value. For purposes of this
Section 10.2, "fair market value" of a share of Series Preferred (or Common
Stock if the Series Preferred has been automatically converted into Common
Stock) as of a particular date (the "Determination Date") shall mean:

                  (i)   If the Conversion Right is exercised in connection with
and contingent upon a Public Offering, and if the Company's Registration
Statement relating to such Public Offering ("Registration Statement") has been
declared effective by the Securities and Exchange Commission, then the initial
"Price to Public" specified in the final prospectus with respect to such
offering.

                  (ii)  If the Conversion Right is not exercised in connection
with and contingent upon a Public Offering, then as follows:

            (A) If traded on a securities exchange, the fair market value of the
      Common Stock shall be deemed to be the average of the closing prices of
      the Common Stock on such exchange over the 30-day period ending five
      business days prior to the Determination Date, and the fair market value
      of the Series Preferred shall be deemed to be such fair market value of
      the Common Stock multiplied by the number of shares of Common Stock into
      which each share of Series Preferred is then convertible;

            (B) If traded on the Nasdaq Stock Market or other over-the-counter
      system, the fair market value of the Common Stock shall be deemed to be
      the average of the closing bid prices of the Common Stock over the 30-day
      period ending five business days prior to the Determination Date, and the
      fair market value of the Series Preferred shall be deemed to be such fair
      market value of the Common Stock multiplied by the number of shares of
      Common Stock into which each share of Series Preferred is then
      convertible; and

            (C) If there is no public market for the Common Stock, then fair
      market value shall be determined by mutual agreement of the holder of this
      Warrant and the Company.

      10.3  Exercise Prior to Expiration. To the extent this Warrant is not
previously exercised as to all of the Shares subject hereto, and if the fair
market value of one share of the Series Preferred is greater than the Warrant
Price then in effect, this Warrant shall be deemed automatically exercised
pursuant to Section 10.2 above (even if not surrendered) immediately before its
expiration. For purposes of such automatic exercise, the fair market value of
one share of the Series Preferred upon such expiration shall be determined
pursuant to Section 10.2(c). To the extent this Warrant or any portion thereof
is deemed automatically exercised pursuant to this Section 10.3, the Company
agrees to promptly notify the holder hereof of the number of Shares, if any, the
holder hereof is to receive by reason of such automatic exercise.

                                       -9-

<PAGE>

      11.   Representations and Warranties. The Company represents and warrants
to the holder of this Warrant as follows:

            (a) This Warrant has been duly authorized and executed by the
Company and is a valid and binding obligation of the Company enforceable in
accordance with its terms, subject to laws of general application relating to
bankruptcy, insolvency and the relief of debtors and the rules of law or
principles at equity governing specific performance, injunctive relief and other
equitable remedies;

            (b) The Shares have been duly authorized and reserved for issuance
by the Company and, when issued in accordance with the terms hereof, will be
validly issued, fully paid and non-assessable;

            (c) The rights, preferences, privileges and restrictions granted to
or imposed upon the Series Preferred and the holders thereof are as set forth in
the Charter, and on the Date of Grant, each share of the Series Preferred
represented by this Warrant is convertible into 1.1111 shares of Common Stock;

            (d) The shares of Common Stock issuable upon conversion of the
Shares have been duly authorized and reserved for issuance by the Company and,
when issued in accordance with the terms of the Charter will be validly issued,
fully paid and nonassessable;

            (e) The execution and delivery of this Warrant are not, and the
issuance of the Shares upon exercise of this Warrant in accordance with the
terms hereof will not be, inconsistent with the Company's Charter or by-laws, do
not and will not contravene any law, governmental rule or regulation, judgment
or order applicable to the Company, and do not and will not conflict with or
contravene any provision of, or constitute a default under, any indenture,
mortgage, contract or other instrument of which the Company is a party or by
which it is bound or require the consent or approval of, the giving of notice
to, the registration or filing with or the taking of any action in respect of or
by, any Federal, state or local government authority or agency or other person,
except for the filing of notices pursuant to federal and state securities laws,
which filings will be effected by the time required thereby; and

            (f) There are no actions, suits, audits, investigations or
proceedings pending or, to the knowledge of the Company, threatened against the
Company in any court or before any governmental commission, board or authority
which, if adversely determined, will have a material adverse effect on the
ability of the Company to perform its obligations under this Warrant.

            (g) The number of shares of Common Stock of the Company outstanding
on the date hereof, on a fully diluted basis (assuming the conversion of all
outstanding convertible securities and the exercise of all outstanding options
and warrants), does not exceed 12,000,000 shares.

      12.   Modification and Waiver. This Warrant and any provision hereof may
be changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of the same is sought.

                                      -10-

<PAGE>

      13.   Notices. Any notice, request, communication or other document
required or permitted to be given or delivered to the holder hereof or the
Company shall be delivered, or shall be sent by certified or registered mail,
postage prepaid, to each such holder at its address as shown on the books of the
Company or to the Company at the address indicated therefor on the signature
page of this Warrant.

      14.   Binding Effect on Successors. This Warrant shall be binding upon any
corporation succeeding the Company by merger, consolidation or acquisition of
all or substantially all of the Company's assets, and all of the obligations of
the Company relating to the Series Preferred issuable upon the exercise or
conversion of this Warrant shall survive the exercise, conversion and
termination of this Warrant and all of the covenants and agreements of the
Company shall inure to the benefit of the successors and assigns of the holder
hereof.

      15.   Lost Warrants or Stock Certificates. The Company covenants to the
holder hereof that, upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant or any
stock certificate and, in the case of any such loss, theft or destruction, upon
receipt of an indemnity reasonably satisfactory to the Company, or in the case
of any such mutilation upon surrender and cancellation of such Warrant or stock
certificate, the Company will make and deliver a new Warrant or stock
certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated
Warrant or stock certificate.

      16.   Descriptive Headings. The descriptive headings of the several
paragraphs of this Warrant are inserted for convenience only and do not
constitute a part of this Warrant. The language in this Warrant shall be
construed as to its fair meaning without regard to which party drafted this
Warrant.

      17.   Governing Law. This Warrant shall be construed and enforced in
accordance with, and the rights of the parties shall be governed by, the laws of
the State of California, without regard to conflicts of law provisions thereof.

      18.   Survival of Representations. Warranties and Agreements. All
representations and warranties of the Company and the holder hereof contained
herein shall survive the Date of Grant, the exercise or conversion of this
Warrant (or any part hereof) or the termination or expiration of rights
hereunder. All agreements of the Company and the holder hereof contained herein
shall survive indefinitely until, by their respective terms, they are no longer
operative.

      19.   Remedies. In case any one or more of the covenants and agreements
contained in this Warrant shall have been breached, the holders hereof (in the
case of a breach by the Company), or the Company (in the case of a breach by a
holder), may proceed to protect and enforce their or its rights either by suit
in equity and/or by action at law, including, but not limited to, an action for
damages as a result of any such breach and/or an action for specific performance
of any such covenant or agreement contained in this Warrant.

                                      -11-

<PAGE>

      20.   No Impairment of Rights. The Company will not, by amendment of its
Charter or through any other means, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good
faith assist in the carrying out of all such terms and in the taking of all such
action as may be necessary or appropriate in order to protect the rights of the
holder of this Warrant against impairment.

      21.   Severability. The invalidity or unenforceability of any provision of
this Warrant in any jurisdiction shall not affect the validity or enforceability
of such provision in any other jurisdiction, or affect any other provision of
this Warrant, which shall remain in full force and effect.

      22.   Recovery of Litigation Costs. If any legal action or other
proceeding is brought for the enforcement of this Warrant, or because of an
alleged dispute, breach, default, or misrepresentation in connection with any of
the provisions of this Warrant, the successful or prevailing party or parties
shall be entitled to recover reasonable attorneys' fees and other costs incurred
in that action or proceeding, in addition to any other relief to which it or
they may be entitled.

      23.   Entire Agreement: Modification. This Warrant constitutes the entire
agreement between the parties pertaining to the subject matter contained in it
and supersedes all prior and contemporaneous agreements, representations, and
undertakings of the parties, whether oral or written, with respect to such
subject matter.

      24.   Market Stand-Off Agreement. The holder of this Warrant hereby agrees
that, during the period of duration specified by the Company or an underwriter
of capital stock or other securities of the Company, following the effective
date of a registration statement of the Company filed under the Act, its shall
not, to the extent requested by the Company and such underwriter, directly or
indirectly sell, offer to sell, contract to sell (including, without limitation,
any short sale), grant any option to purchase or otherwise transfer or dispose
of (other than to donees who agree to be similarly bound) and securities of the
Company held by it at any time during such period except capital stock included
in such registration; provided, however, that:

            (a)   all executive officers and directors of the Company and all
holders of one percent (1%) or greater of the Company's capital stock enter
into similar agreements; and

            (b)   such period shall not exceed one hundred eighty (180) days
beginning the day after the effective date of such registration statement.

In order to enforce the foregoing covenant, the Company may impose stop-transfer
instructions with respect to the stock of the holder of this Warrant until the
end of such period.

                                      -12-

<PAGE>

      The Company has caused this Warrant to be duly executed and delivered as
of the Date of Grant specified above.

                                        ADEZA BIOMEDICAL CORPORATION

                                        By    /s/ Emory V. Anderson
                                              ----------------------------------
                                        Title    President

                                        Address: 1240 Elko Drive
                                                 Sunnyvale, California 94089

                                      -13-

<PAGE>

                                   EXHIBIT A-1

                               NOTICE OF EXERCISE

To: ADEZA BIOMEDICAL CORPORATION

      1.    The undersigned hereby:

            [ ]   elects to purchase_____shares of [Series 3 Preferred Stock]
                  [Common Stock] of ADEZA BIOMEDICAL CORPORATION pursuant
                  to the terms of the attached Warrant, and tenders
                  herewith payment of the purchase price of such shares in
                  full, or

            [ ]   elects to exercise its net issuance rights pursuant to Section
                  10.2 of the attached Warrant with respect to____Shares
                  of [Series 3 Preferred Stock] [Common Stock].

      2.    Please issue a certificate or certificates representing______shares
in the name of the undersigned or in such other name or names as are specified
below:

                      _____________________________________
                                     (Name)

                      _____________________________________

                      _____________________________________
                                    (Address)

      3.    The undersigned represents that the aforesaid shares are being
acquired for the account of the undersigned for investment and not with a view
to, or for resale in connection with, the distribution thereof and that the
undersigned has no present intention of distributing or reselling such shares,
all except as in compliance with applicable securities laws.

                                           _____________________________________
                                           (Signature)

____________
   (Date)

                                      -14-

<PAGE>

                                   EXHIBIT A-2

                               NOTICE OF EXERCISE

To: ADEZA BIOMEDICAL CORPORATION (the "Company")

      1.    Contingent upon and effective immediately prior to the closing (the
"Closing") of the Company's public offering contemplated by the Registration
Statement on Form S__, filed_________ __________, 19__, the undersigned hereby:

            [ ]   elects to purchase_____shares of [Series 3 Preferred
                  Stock] [Common Stock] of the Company (or such lesser
                  number of shares as may be sold on behalf of the
                  undersigned at the Closing) pursuant to the terms of the
                  attached Warrant, or

            [ ]   elects to exercise its net issuance rights pursuant to
                  Section 10.2 of the attached Warrant with respect
                  to_______Shares of [Series 3 Preferred Stock] [Common
                  Stock].

      2.    Please deliver to the custodian for the selling shareholders a stock
certificate representing such_________shares.

      3.    The undersigned has instructed the custodian for the selling
shareholders to deliver to the Company $____________or, if less, the net
proceeds due the undersigned from the sale of shares in the aforesaid public
offering. If such net proceeds are less than the purchase price for such shares,
the undersigned agrees to deliver the difference to the Company prior to the
Closing.

                                           _____________________________________
                                           (Signature)

____________
   (Date)

                                      -15-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]